Semax, selank, and nootropic peptides: separating hype from human data

What did @psl.m4hran actually say?

Honestly? Not much that's medically analyzable. The transcript is a fragment of what sounds like a song or spoken-word clip, referencing hair and dreads with zero pharmacological content. The caption, though, does the heavy lifting: it claims a compound (implied from context: semax, selank, or a related peptide) "may even increase intellect relative from baseline regardless of 19-nor stress." That's the claim worth examining.

The hashtags, including #nootropics, #cognitiveenhancement, and #roids, place this squarely in the peptide-plus-anabolic-steroid optimization space. The "19-nor" reference points to 19-nortestosterone derivatives like nandrolone or trenbolone, compounds known to carry cognitive and mood side effects. So the actual thesis here is: a peptide nootropic can offset or outperform the cognitive drag from a 19-nor steroid cycle. That's a specific, testable claim, and it deserves a real answer.

Does the science back this up?

Partially, and with significant caveats. Semax has the most credible data in this space, but almost none of it involves co-administration with anabolic steroids. The claim that it raises cognitive baseline "regardless of 19-nor stress" is not supported by any published human trial.

Semax (ACTH 4-7 Pro8-Gly9-Pro10) is a synthetic peptide derived from adrenocorticotropic hormone. It has demonstrated neuroprotective and BDNF-upregulating effects in rodent models (Dolotov et al., 2006, Journal of Molecular Neuroscience). A small Russian clinical study showed improvements in attention and memory in stroke recovery patients (Lebedeva et al., 2008, Zhurnal Nevrologii i Psikhiatrii). These are not healthy adults stacking it with trenbolone.

19-nor steroids, particularly trenbolone, have documented negative effects on neuroplasticity and hippocampal function in rodent studies (Tamanna et al., 2018, Frontiers in Neuroscience). The idea that semax could simply neutralize that neurological burden is a hypothesis, not a finding. No peer-reviewed study has tested this combination in any population.

What did they get wrong (or right)?

The caption oversells the evidence. Saying semax "may even increase intellect relative from baseline" conflates rodent BDNF data with human cognitive enhancement, which is a jump the literature does not support in healthy subjects. "Regardless of 19-nor stress" is the part that really falls apart. There is no clinical data on peptide nootropics as a protective co-administration strategy during anabolic steroid use.

To be fair, the framing uses "may," which is at least epistemically honest. Semax is not a fraud compound. It has a real pharmacological mechanism, real receptor activity at melanocortin receptors, and real neuroprotective signals in preclinical work. Selank similarly shows anxiolytic properties in animal models (Semenova et al., 2010, Bulletin of Experimental Biology and Medicine) and may reduce the psychological stress component of heavy androgenic cycles, though again, no direct comparative data exists.

What they got wrong is the certainty implied by packaging preclinical rodent findings as a practical protocol for people running nandrolone or trenbolone. That's a meaningful gap.

What should you actually know?

If you're researching peptide nootropics in the context of anabolic steroid use, here's what the honest summary looks like. Semax and selank have pharmacological plausibility. Neither is approved by the FDA for any indication. Both are primarily studied in Russia, in clinical populations with neurological conditions, not healthy adults pursuing cognitive optimization.

19-nor steroids carry real neurological risk. Trenbolone in particular has been associated with anxiety, aggression, and potential hippocampal damage in preclinical models. The idea that a nasal peptide spray resolves that risk profile is not backed by evidence. It may attenuate some symptoms, particularly anxiety-adjacent ones via selank's GABAergic activity, but that's different from protecting cognitive baseline.

• No human RCT has tested semax or selank alongside anabolic steroids.
• BDNF upregulation in rodents does not automatically translate to measurable IQ-adjacent gains in humans.
• Anyone combining these compounds is operating well outside studied parameters, meaning they carry personal risk with no clinical safety net.
• Telehealth platforms operating under regulatory oversight do not prescribe compounded peptides for off-label cognitive enhancement stacked with non-prescribed anabolic steroids.